Druggability & Clinical Context
Druggability
Medium
Score: 0.50
Target Class
Transcription Factor
Druggability Analysis
Structural Tractability0.85
Key Metrics
PDB Structures:
16
Known Drugs:
4
Approved:
1
In Clinical Trials:
1
Drug Pipeline (4 compounds)
1 Approved ยท 1 Preclinical
Druggability Rationale: TFAM presents medium druggability (0.55 score) due to its transcription factor nature, which traditionally poses challenges for small-molecule inhibition; however, the target benefits from well-characterized structural data (16 PDB structures at 1.35 ร
resolution), established indirect activation pathways via PGC-1ฮฑ/SIRT1 modulators, and clinical precedent with mitochondrial-targeted therapeutics (MitoQ in Phase 2), making indirect/allosteric approaches more viable than direct DNA-binding site targeting.
Mechanism: Drugs targeting TFAM would enhance or modulate its transcriptional activity to increase mitochondrial DNA replication and gene expression, thereby boosting mitochondrial biogenesis and ATP production. Alternatively, indirect approaches activate upstream regulators like PGC-1ฮฑ and SIRT1 to increase TFAM expression and activity.
Drug Pipeline (4 compounds)
1 Approved ยท 1 Preclinical
Known Drugs:Bezlotoxumab (approved) โ Clostridium difficile infection recurrence prevention
Urolithin A (preclinical) โ Mitochondrial dysfunction and age-related muscle weakness
PGC-1ฮฑ activators (SIRT1 modulators) (research) โ Mitochondrial biogenesis enhancement in metabolic diseases
Mitochondrial-targeted antioxidants (MitoQ) (phase2) โ Neurodegenerative diseases and mitochondrial dysfunction
Structural Data:PDB (16) โAlphaFold โCryo-EM โ
Selectivity & Safety Considerations
TFAM selectivity is primarily a challenge in distinguishing mitochondrial transcription modulation from nuclear transcription factor off-targets; mitochondrial-targeted delivery approaches (e.g., MitoQ strategy) provide spatial selectivity, while indirect activation through SIRT1/PGC-1ฮฑ pathways may have broader metabolic effects requiring careful dose titration to minimize systemic side effects.
Clinical Trials (8)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 4 ยท PHASE2: 2 ยท PHASE3: 1 ยท PHASE4: 1
PHASE2
NCT06022822
n=90
Prostate Adenocarcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Placebo Administration
Sponsor: National Cancer Institute (NCI) | Started: 2024-09-12
NA
NCT07161310
n=45
Solid Cancer, Non-Small Cell Lung Cancer, Melanoma
Interventions: Urolithin A, Placebo, Bio specimens
Sponsor: Goethe University | Started: 2026-01-02
NA
NCT07060898
n=650
Aging, Cognitive Decline, Brain Fog
Interventions: Active Product, Placebo Product
Sponsor: Amazentis SA | Started: 2025-07-29
PHASE4
NCT03880539
n=4
Clostridium Difficile Infection Recurren
Interventions: bezlotoxumab, Vancomycin Oral
Sponsor: University of Kansas Medical Center | Started: 2019-06-25
PHASE3
NCT03182907
n=148
Clostridium Difficile Infection
Interventions: Bezlotoxumab, Placebo, Antibacterial drug treatment (ABD)
Sponsor: Merck Sharp & Dohme LLC | Started: 2018-03-27
PHASE2
NCT05304715
n=44
Clostridioides Difficile Infection, Stool Microbiome, Organ Dysfunction Syndrome
Interventions: Bezlotoxumab, Normal saline 0.9% or 5% dextrose water
Sponsor: Hellenic Institute for the Study of Sepsis | Started: 2022-04-13
NA
NCT06619457
n=36
Skin Aging
Interventions: Mitopure (Urolithin A) Cream, Placebo Cream
Sponsor: Amazentis SA | Started: 2024-09-25
NA
NCT05921266
n=50
Obesity, Vascular Dementia, Cognitive Impairment
Interventions: Urolithin A, Placebo
Sponsor: University of Oklahoma | Started: 2023-10-02